Bristol Myers Squibb (BMY) Cash & Equivalents Growth (5y) (2014 - 2026)

Bristol Myers Squibb (BMY) Cash & Equivalents Growth (5y) (2014 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -2.71%
Dec 31, 2025 -6.84%
Sep 30, 2025 -4.15%
Jun 30, 2025 -8.77%
Mar 31, 2025 -7.22%
Dec 31, 2024 -3.47%
Sep 30, 2024 -23.69%
Jun 30, 2024 -26.02%
Mar 31, 2024 4.93%
Dec 31, 2023 10.65%
Sep 30, 2023 6.80%
Jun 30, 2023 10.86%
Mar 31, 2023 10.98%
Dec 31, 2022 10.97%
Sep 30, 2022 10.74%
Jun 30, 2022 25.38%
Mar 31, 2022 25.90%
Dec 31, 2021 26.96%
Sep 30, 2021 31.59%
Jun 30, 2021 30.31%